Literature DB >> 1698859

Synthetic peptides containing T and B cell epitopes from human immunodeficiency virus envelope gp120 induce anti-HIV proliferative responses and high titers of neutralizing antibodies in rhesus monkeys.

M K Hart1, T J Palker, T J Matthews, A J Langlois, N W Lerche, M E Martin, R M Scearce, C McDanal, D P Bolognesi, B F Haynes.   

Abstract

We have previously described a synthetic peptide (T1-SP10) derived from two noncontiguous regions of HTLVIIIB envelope gp120 (T1, amino acids 428-443; SP10, amino acids 303-321) that induced type-specific anti-HIV neutralizing antibodies and T cell proliferative responses against native HIV gp120 when used as a carrier-free immunogen in goats. In this study, HTLVIIIB T1-SP10 synthetic peptides were used to immunize rhesus monkeys to determine if the peptides were capable of eliciting HIV-specific neutralizing antibody and proliferative responses in primates. Four compounds (alum, polyA:polyU, threonyl-muramyldipeptide (MDP) and IFA) were also compared for efficacy as adjuvants in this system. Rhesus monkeys immunized with T1-SP10 peptides generated high titers of antibodies against the immunogens and also against HTLVIIIB gp120. Sera from all four animals given T1-SP10 in IFA or threonyl-MDP neutralized infection by HTLVIIIB and blocked virus-dependent cell fusion events. A peak neutralization titer of 1:940 was seen in one animal given IFA (19600) and a titer of 1:900 was seen in one of the monkeys (17371) given threonyl-MDP. Proliferative responses of immune rhesus PBMC to T1-SP10 appeared after the first injection. After eight immunizations, two of eight monkeys (one injected with peptides in threonyl-MDP and one given peptides in IFA) had PBMC proliferative responses to native HTLVIIIB gp120. These data demonstrate that the carrier-free T1-SP10 synthetic peptide construct can induce high titers of neutralizing anti-HIV antibody responses and PBMC proliferative responses to HIV in primates.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1698859

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

1.  A synthetic peptide to the E glycoprotein of Murray Valley encephalitis virus defines multiple virus-reactive T- and B-cell epitopes.

Authors:  J H Mathews; J T Roehrig; J R Brubaker; A R Hunt; J E Allan
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

2.  Cross-reactive T-cell proliferative responses to V3 peptides corresponding to different geographical HIV-1 isolates in HIV-seropositive individuals.

Authors:  P N Nehete; P C Johnson; S J Schapiro; R B Arlinghaus; K J Sastry
Journal:  J Clin Immunol       Date:  1996-03       Impact factor: 8.317

3.  Priming of anti-human immunodeficiency virus (HIV) CD8+ cytotoxic T cells in vivo by carrier-free HIV synthetic peptides.

Authors:  M K Hart; K J Weinhold; R M Scearce; E M Washburn; C A Clark; T J Palker; B F Haynes
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-01       Impact factor: 11.205

4.  Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization.

Authors:  Curtis P Bradney; Gregory D Sempowski; Hua-Xin Liao; Barton F Haynes; Herman F Staats
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

5.  Deficient synthesis of class-switched, HIV-neutralizing antibodies to the CD4 binding site and correction by electrophilic gp120 immunogen.

Authors:  Stephanie A Planque; Yukie Mitsuda; Vida Chitsazzadeh; Santhi Gorantla; Larisa Poluektova; Yasuhiro Nishiyama; Christina Ochsenbauer; Mary-Kate Morris; Gopal Sapparapu; Carl V Hanson; Richard J Massey; Sudhir Paul
Journal:  AIDS       Date:  2014-09-24       Impact factor: 4.177

6.  Synthetic peptides representing sequences within gp41 of HIV as immunogens for murine T- and B-cell responses.

Authors:  L E Brown; D O White; C Agius; B E Kemp; N Yatzakis; P Poumbourios; D A McPhee; D C Jackson
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

7.  Human immunodeficiency virus type 1 major neutralizing determinant exposed on hepatitis B surface antigen particles is highly immunogenic in primates.

Authors:  K Schlienger; M Mancini; Y Rivière; D Dormont; P Tiollais; M L Michel
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

8.  Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity.

Authors:  Barney S Graham; M Juliana McElrath; Michael C Keefer; Kyle Rybczyk; David Berger; Kent J Weinhold; Janet Ottinger; Guido Ferarri; David C Montefiori; Don Stablein; Carol Smith; Richard Ginsberg; John Eldridge; Ann Duerr; Pat Fast; Barton F Haynes
Journal:  PLoS One       Date:  2010-08-10       Impact factor: 3.240

9.  HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein vaccination or HIV-1 infection.

Authors:  Mattia Bonsignori; M Anthony Moody; Robert J Parks; T Matt Holl; Garnett Kelsoe; Charles B Hicks; Nathan Vandergrift; Georgia D Tomaras; Barton F Haynes
Journal:  J Immunol       Date:  2009-07-22       Impact factor: 5.422

10.  Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine.

Authors:  S P Mossman; F Bex; P Berglund; J Arthos; S P O'Neil; D Riley; D H Maul; C Bruck; P Momin; A Burny; P N Fultz; J I Mullins; P Liljeström; E A Hoover
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.